Brief: Resverlogix Says A Second Publication Shortlists Co's Clinical Candidate Apabetalone For Its Potential Covid-19 Effectiveness
26/10/2020 12:26
Oct 26 (Reuters) - Resverlogix Corp RVX.TO :
* A SECOND PUBLICATION SHORTLISTS RESVERLOGIX CLINICAL
CANDIDATE
APABETALONE FOR ITS POTENTIAL COVID-19 EFFECTIVENESS INCLUDING
REDUCING CYTOKINE STORMS
Source text for Eikon: ID:nGNX81XllH
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment